Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07751341 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma

Name: A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma — clinical trial record (NCT07751341)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorSuzhou Suncadia Biopharmaceuticals Co., Ltd.

Started2026-09-07

View on ClinicalTrials.gov ↗

Amendment history

2026-09-17

Recruitment opened

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

75 trials monitored

See 7 trials at risk

Esophageal Cancer

1,010 trials monitored

See 51 trials at risk

An open-label, multicenter, randomized, phase II clinical trial to evaluate the safety, tolerability and efficacy of SHR-9839(sc) as monotherapy or in combination with chemotherapy plus adebelimab in patients with advanced esophageal squamous cell carcinoma (ESCC).

Trial Details

NCT Number	NCT07751341
Lead Sponsor	Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions	Advanced Esophageal Squamous Cell Carcinoma
Enrollment	84 participants
Start Date	2026-09-07
Primary Completion	2027-12 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-09-16